PAPER Austrom MG, Dickinson SL, Denny SS, Matthews BR, Gao S, Lu Y

Frontotemporal dementia caregivers and researchers: partnering for brain donation.

Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):477-83. PubMed: 22021861

PAPER Sherman A, Bowser R, Grasso D, Power B, Milligan C, Jaffa M, Cudkowicz M

Proposed BioRepository platform solution for the ALS research community.

Amyotroph Lateral Scler. 2011 Jan;12(1):11-6. PubMed: 21128868

PAPER Qureshi M, Shui A, Dibernardo AB, Brown RH, Schoenfeld DA, Cudkowicz ME

Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis.

Amyotroph Lateral Scler. 2008 Dec;9(6):369-74. PubMed: 18608098

PAPER Mendonça DM, Martins SC, Higashi R, Muscara MN, Neto VM, Chimelli L, Martinez AM

Neurofilament heavy subunit in cerebrospinal fluid: a biomarker of amyotrophic lateral sclerosis?

Amyotroph Lateral Scler. 2011 Mar;12(2):144-7. PubMed: 21198418

PAPER Shefner JM, Watson ML, Simionescu L, Caress JB, Burns TM, Maragakis NJ, Benatar M, David WS, Sharma KR, Rutkove SB

Multipoint incremental motor unit number estimation as an outcome measure in ALS.

Neurology. 2011 Jul 19;77(3):235-41. PubMed: 21676915

PAPER Shefner JM

Statistical motor unit number estimation and ALS trials: the effect of motor unit instability.

Suppl Clin Neurophysiol. 2009;60:135-41. PubMed: 20715375

PAPER Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D,

Revised statistical motor unit number estimation in the Celecoxib/ALS trial.

Muscle Nerve. 2007 Feb;35(2):228-34. PubMed: 17058270

PAPER Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME

The natural history of ALS is changing: improved survival.

Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):324-31. PubMed: 19922119

PAPER Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, Goslin KL, Graves MC, McCluskey LF, McVey AL, Mozaffar T, Florence JM, Pestronk A, Ross M, Simpson EP, Appel SH,

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.

Neurology. 2011 Sep 6;77(10):973-9. PubMed: 21813790

PAPER Chiò A, Canosa A, Gallo S, Cammarosano S, Moglia C, Fuda G, Calvo A, Mora G,

ALS clinical trials: do enrolled patients accurately represent the ALS population?

Neurology. 2011 Oct 11;77(15):1432-7. PubMed: 21956723

PAPER Al-Refaie WB, Vickers SM, Zhong W, Parsons H, Rothenberger D, Habermann EB

Cancer trials versus the real world in the United States.

Ann Surg. 2011 Sep;254(3):438-42; discussion 442-3. PubMed: 21775882

PAPER Bedlack RS, Pastula DM, Welsh E, Pulley D, Cudkowicz ME

Scrutinizing enrollment in ALS clinical trials: room for improvement?

Amyotroph Lateral Scler. 2008 Oct;9(5):257-65. PubMed: 18608092

PAPER Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M

Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.

Neurology. 2005 Dec 13;65(11):1834-6. PubMed: 16344537

PAPER Penn RD, Kroin JS, York MM, Cedarbaum JM

Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).

Neurosurgery. 1997 Jan;40(1):94-9; discussion 99-100. PubMed: 8971830

PAPER Aebischer P, Schluep M, Déglon N, Joseph JM, Hirt L, Heyd B, Goddard M, Hammang JP, Zurn AD, Kato AC, Regli F, Baetge EE

Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients.

Nat Med. 1996 Jun;2(6):696-9. PubMed: 8640564